Table 3.

Multivariate analysis: covariates impact on overall survival.

Variable	Reference category parameter		DF	Chi-square	Pr > Chi-square	Hazard ratio	95% hazard ratio confidence limits
Cohort	1 Nivolumab	2 Docetaxel	1	14.195	0.0002	1.888	1.356	2.627
Gender	Male	Female	1	0.036	0.8505	1.033	0.737	1.448
Age	>75	18-59	1	1.247	0.2641	0.762	0.473	1.227
		60-64	1	0.008	0.9285	0.979	0.619	1.549
		65-69	1	2.102	0.1471	1.367	0.896	2.085
		70-74	1	2.261	0.1327	1.376	0.908	2.085
Smoking habits	Yes	Missing	1	1.367	0.2424	0.735	0.439	1.231
	Yes	No	1	0.059	0.8074	1.059	0.669	1.677
Histology	Adenocarcinoma	Non-adenocarcinoma	1	2.366	0.1240	1.291	0.932	1.787
CCI_GT_7	No	Yes	1	2.163	0.1413	1.494	0.875	2.55
ECOG PS 0-1	Yes	Missing	1	0.730	0.3929	1.159	0.826	1.626
	Yes	No	1	8.195	0.0042	2.389	1.316	4.338
Number of metastatic sites	≤2	>2	1	2.272	0.1318	0.677	0.408	1.124
Presence of lung metastasis	No	Yes	1	2.005	0.1568	1.263	0.914	1.745
Presence of liver metastasis	No	Yes	1	4.242	0.0394	1.505	1.02	2.221
Presence of brain metastasis	No	Yes	1	4.202	0.0404	1.592	1.021	2.482
Presence of pleural metastasis	No	Yes	1	3.529	0.0603	1.461	0.984	2.17
Presence of bone metastasis	No	Yes	1	6.823	0.0090	1.640	1.131	2.377
Presence of adrenal gland metastasis	No	Yes	1	7.759	0.0053	1.780	1.186	2.67
Presence of lymph node metastasis	No	Yes	1	3.567	0.0589	1.438	0.986	2.097
Presence of another metastasis	No	Yes	1	2.629	0.1049	1.536	0.914	2.581
Progression to previous treatment lines	Yes	No	1	5.827	0.0158	0.653	0.462	0.923
Further treatment	No	Yes	1	12.390	0.0004	0.582	0.431	0.787

Values in bold are statistically significant.

Abbreviations: CCI, Charlson Comorbidity Index; DF, degree of freedom; ECOG PS, Eastern Cooperative Oncology Group performance status PS.